- Scorpius Holdings Inc., a CDMO, has successfully validated its microbial facilities for cGMP microbial biologic drugs manufacturing.
- The company is streamlining operations by transitioning environmental monitoring responsibilities to internal teams.
Scorpius Holdings Inc., an integrated contract development and manufacturing organization (CDMO), has announced a significant achievement in the pharmaceutical industry. The company’s microbial facilities have been successfully validated, signifying that they are now officially approved to manufacture current Good Manufacturing Practice (cGMP) microbial biologic drugs.
This validation is a testament to Scorpius’ ability to meet the high standards required for contract manufacturing of microbial biologics, both from regulatory bodies and clients. It demonstrates the company’s commitment to quality and efficiency in its operations.
In addition to the facility qualifications, Scorpius is also making strategic changes to its operations. The company is transitioning environmental monitoring responsibilities from third-party services to internal teams. This shift is expected to enhance efficiency and further improve the company’s ability to deliver quality biomanufacturing services.
Jeff Wolf, CEO of Scorpius Holdings, expressed his enthusiasm about the validation and the company’s future. He stated, “Scorpius has experienced strong interest in our microbial capabilities, and we continue to add additional opportunities to our pipeline for 2024 and 2025. This validation confirms our commitment to high-quality, state-of-the-art microbial production. We are dedicated to leveraging our advanced capabilities to support our clients’ needs and contributing to the advancement of breakthrough therapies.”
